<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CICLOPIROX- ciclopirox shampoo </strong><br>Taro Pharmaceuticals U.S.A., Inc.<br></p></div>
<h1>Ciclopirox Shampoo, 1%</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx Only</span></p>
<p>FOR TOPICAL USE ONLY<br>NOT FOR OPHTHALMIC, ORAL OR INTRAVAGINAL USE<br>KEEP OUT OF REACH OF CHILDREN</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Ciclopirox Shampoo 1% contains the synthetic antifungal agent, ciclopirox.</p>
<p>Each gram (equivalent to 0.96 mL) of Ciclopirox Shampoo contains 10 mg ciclopirox in a shampoo base consisting of disodium laureth sulfosuccinate, laureth-2, purified water USP, sodium chloride USP and sodium laureth sulfate.</p>
<p>Ciclopirox Shampoo is a colorless to yellowish, translucent solution. The chemical name for ciclopirox is 6-cyclohexyl-1-hydroxy-4-methyl-2(1<span class="Italics">H</span>)-pyridone, with the empirical formula C<span class="Sub">12</span>H<span class="Sub">17</span>NO<span class="Sub">2</span> and a molecular weight of 207.27. The CAS Registry Number is [29342-05-0]. The chemical structure is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b44b190b-8e2a-4937-a6c5-92f37911e7f8&amp;name=ciclopirox-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Ciclopirox is a hydroxypyridone antifungal agent although the relevance of this property for the indication of <span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">seborrheic dermatitis</span> is not known. Ciclopirox acts by chelation of polyvalent cations (Fe<span class="Sup">3+</span> or Al<span class="Sup">3+</span>), resulting in the inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics and Pharmacodynamics</h2>
<p class="First">In a study in patients with <span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">seborrheic dermatitis</span> of the scalp, application of 5 mL ciclopirox shampoo 1% twice weekly for 4 weeks, with an exposure time of 3 minutes per application, resulted in detectable serum concentrations of ciclopirox in 6 out of 18 patients. The serum concentrations measured throughout the dosing interval on Days 1 and 29 ranged from 10.3 ng/mL to 13.2 ng/mL. Total urinary excretion of ciclopirox was less than 0.5% of the administered dose.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-3.3"></a><p></p>
<h2>CLINICAL STUDIES</h2>
<p class="First">In two randomized, double-blind clinical trials, patients 16 years and older with <span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">seborrheic dermatitis</span> of the scalp applied Ciclopirox Shampoo or its vehicle two times per week for 4 weeks. Patients who were immunocompromised, those with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> or <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>, women of childbearing potential not using adequate contraception, and pregnant or lactating women were excluded from the clinical studies. An evaluation of the overall status of the <span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">seborrheic dermatitis</span>, and the presence and severity of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, and scaling, was made at week 4, using a scale of 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = pronounced, and 5 = severe. Effective treatment was defined as achieving a score of 0 (or a score of 1 if the baseline score was ≥ 3) simultaneously for status of the <span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">seborrheic dermatitis</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, and scaling at Week 4. Ciclopirox shampoo was shown to be statistically significantly more effective than vehicle in both studies. Efficacy results for the two studies are presented in the following table.</p>
<table width="75%">
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="34%">
<col align="left" valign="top" width="33%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="center" colspan="3">Effective Treatment Rates at Week 4 in Studies 1 and 2</th></tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="left">Ciclopirox Shampoo</th>
<th class="Rrule" align="left">Vehicle</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Study 1</td>
<td class="Rrule" align="left">220/380 (58%)</td>
<td class="Rrule" align="left">60/192 (31%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Study 2</td>
<td class="Rrule" align="left">65/250 (26%)</td>
<td class="Rrule" align="left">32/249 (13%)</td>
</tr>
</tbody>
</table>
<p>Efficacy for black patients was not demonstrated, although only 53 black patients were enrolled in the two pivotal studies.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="section-3.4"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Ciclopirox is fungicidal<span class="Italics"> in vitro </span>against<span class="Italics"> Malassezia furfur </span>(<span class="Italics">Pityrosporum </span>spp.),<span class="Italics"> P. ovale</span>, and<span class="Italics"> P. orbiculare</span>. Ciclopirox acts by chelation of polyvalent cations (Fe<span class="Sup">3+</span> or Al<span class="Sup">3+</span>), resulting in the inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell.</p>
<p>The clinical significance of antifungal activity in the treatment of <span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">seborrheic dermatitis</span> is not known.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><span class="Bold">Ciclopirox Shampoo is indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">seborrheic dermatitis</span> of the scalp in adults.</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Ciclopirox Shampoo is contraindicated in individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Ciclopirox Shampoo is not for ophthalmic, oral, or intravaginal use.</p>
<p><span class="Bold">Keep out of reach of children</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">If a reaction suggesting sensitivity or irritation should occur with the use of Ciclopirox Shampoo, treatment should be discontinued and appropriate therapy instituted.</p>
<p>Contact of Ciclopirox Shampoo with the eyes should be avoided. If contact occurs, rinse thoroughly with water.</p>
<p><span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">Seborrheic dermatitis</span> may appear at puberty, however, no clinical studies have been done in patients younger than 16 years.</p>
<p>In patients with lighter hair color, <span class="product-label-link" type="condition" conceptid="4242607" conceptname="Hair discoloration">hair discoloration</span> has been rarely reported.</p>
<p>There is no relevant clinical experience with patients who have a history of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> (e.g., extensive, persistent, or unusual distribution of dermatomycoses, recent or recurring <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, or persistent herpes simplex), who are immunocompromised (e.g., HIV-infected patients and transplant patients), or who have a <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">diabetic neuropathy</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">The patient should be instructed to:</p>
<ol class="Arabic">
<li>Use Ciclopirox Shampoo as directed by the physician. Avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water. Ciclopirox Shampoo is for external use on the scalp only. Do not swallow.</li>
<li>Use the medication for <span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">seborrheic dermatitis</span> for the full treatment time even though symptoms may have improved. Notify the physician if there is no improvement after 4 weeks.</li>
<li>Inform the physician if the area of application shows signs of increased irritation (<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, burning, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or oozing) indicative of possible <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</li>
<li>Not use the medication for any disorder other than that for which it is prescribed.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, and Impairment of Fertility</h2>
<p class="First">Long-term animal studies have not been performed to evaluate the carcinogenic potential of Ciclopirox Shampoo or ciclopirox.</p>
<p>The following in vitro genotoxicity tests have been conducted with ciclopirox: evaluation of gene mutation in the Ames<span class="Italics"> <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> </span>and<span class="Italics"> E. coli </span>assays (negative); chromosome aberration assays in V79 Chinese hamster lung fibroblast cells, with and without metabolic activation (positive); chromosome aberration assays in V79 Chinese hamster lung fibroblast cells in the presence of supplemental Fe<span class="Sup">3+</span>, with and without metabolic activation (negative); gene mutation assays in the HGPRT-test with V79 Chinese hamster lung fibroblast cells (negative); and a primary DNA damage assay (i.e., unscheduled DNA synthesis assay in A549 human cells) (negative). An<span class="Italics"> in vitro </span>cell transformation assay in BALB/c 3T3 cells was negative for cell transformation. In an<span class="Italics"> in vivo </span>Chinese hamster bone marrow cytogenetic assay, ciclopirox was negative for chromosome aberrations at a dosage of 5000 mg/kg body weight.</p>
<p>A combined oral fertility and embryofetal developmental study was conducted in rats with ciclopirox olamine. No effect on fertility or reproductive performance was noted at the highest dose tested of 3.85 mg/kg/day ciclopirox (approximately 1.3 times the maximum recommended human dose based on body surface area comparisons).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.4.1"></a><p></p>
<h3>Teratogenic effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.1.1"></a><p></p>
<h4>Pregnancy Category B</h4>
<p class="First">Oral embryofetal developmental studies were conducted in mice, rats, rabbits and monkeys. Ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. No maternal toxicity, embryotoxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> were noted at the highest doses of 77, 125, 80 and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits and monkeys, respectively (approximately 13, 42, 54 and 26 times the maximum recommended human dose based on body surface area comparisons, respectively).</p>
<p>Dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in PEG 400. Ciclopirox olamine was topically administered during the period of organogenesis. No maternal toxicity, embryotoxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> were noted at the highest doses of 92 mg/kg/day and 77 mg/kg/day ciclopirox in rats and rabbits, respectively (approximately 31 and 54 times the maximum recommended human dose based on body surface area comparisons, respectively).</p>
<p>There are no adequate or well-controlled studies of topically applied ciclopirox in pregnant women. Because animal reproduction studies are not always predictive of human response, Ciclopirox Shampoo should be used during pregnancy only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Ciclopirox Shampoo is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">Seborrheic dermatitis</span> may appear at puberty, however, no clinical studies have been done in patients younger than 16 years.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.7"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">In clinical studies, the safety and tolerability of Ciclopirox Shampoo in the population 65 years and older was comparable to that of younger subjects. Results of the efficacy analysis in those patients 65 years and older showed effectiveness in 25 of 85 (29%) patients treated with Ciclopirox Shampoo, and in 15 of 61 (25%) patients treated with the vehicle; due to the small sample size, a statistically significant difference was not demonstrated. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects, but greater sensitivity to adverse effects in some older individuals cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">In 626 patients treated with Ciclopirox Shampoo twice weekly in the two pivotal clinical studies, the most frequent adverse events were increased <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> in 1% of patients, and <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span>, such as burning, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, also in 1% of patients. Other adverse events occurred in individual patients only.</p>
<p>Adverse events that led to early study medication termination in clinical trials occurred in 1.5% (26/1738) of patients treated with Ciclopirox Shampoo and 2.0% (12/661) of patients treated with shampoo vehicle. The most common adverse events leading to termination of study medication in either group was <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span>. In the Ciclopirox Shampoo group, other adverse events included <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span>. In the shampoo vehicle group, other adverse events included <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Wet hair and apply approximately 1 teaspoon (5 mL) of Ciclopirox Shampoo to the scalp. Up to 2 teaspoons (10 mL) may be used for long hair. Lather and leave on hair and scalp for 3 minutes. A timer may be used. Avoid contact with eyes. Rinse off. Treatment should be repeated twice per week for 4 weeks, with a minimum of 3 days between applications.</p>
<p>If a patient with <span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">seborrheic dermatitis</span> shows no clinical improvement after 4 weeks of treatment with Ciclopirox Shampoo, the diagnosis should be reviewed.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<div class="Section" data-sectionCode="44425-7">
<a name="section-10.1"></a><p></p>
<p class="First">Ciclopirox Shampoo, 1% is supplied in 120 mL plastic bottles (NDC 51672-1351-8). Discard unused product after initial treatment duration. Store at 20° - 25°C (68° - 77°F) [See USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<p class="First">Mfd. By: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1</p>
<p>Dist. By:<span class="Bold"> Taro Pharmaceuticals U.S.A., Inc</span>., Hawthorne, NY 10532</p>
<p>Issued: September, 2008</p>
<p>PPK-6006-0<br>266</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 120 mL Carton</h1>
<p class="First"><span class="Bold">120 mL</span></p>
<p><span class="Bold">NDC 51672-1351-8</span></p>
<p><span class="Bold">Ciclopirox<br>Shampoo<br>1%</span></p>
<p>FOR TOPICAL USE ONLY<br>NOT FOR OPHTHALMIC,<br>ORAL OR INTRAVAGINAL<br>USE</p>
<p><span class="Bold">Keep this and all<br>medication out of the<br>reach of children</span></p>
<p><span class="Bold">This package is not<br>child resistant</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">TARO</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 120 mL Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b44b190b-8e2a-4937-a6c5-92f37911e7f8&amp;name=ciclopirox-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CICLOPIROX 		
					</strong><br><span class="contentTableReg">ciclopirox shampoo</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51672-1351</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ciclopirox</strong> (ciclopirox) </td>
<td class="formItem">ciclopirox</td>
<td class="formItem">10 mg  in 0.96 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>disodium laureth sulfosuccinate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>laureth-2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium laureth sulfate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51672-1351-8</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">120 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090269</td>
<td class="formItem">02/23/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Taro Pharmaceuticals U.S.A., Inc.
							(145186370)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Taro Pharmaceuticals Inc.</td>
<td class="formItem"></td>
<td class="formItem">206263295</td>
<td class="formItem">MANUFACTURE(51672-1351)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f8099c2f-42e4-4cd9-9b05-915fdbacf4f5</div>
<div>Set id: b44b190b-8e2a-4937-a6c5-92f37911e7f8</div>
<div>Version: 2</div>
<div>Effective Time: 20111024</div>
</div>
</div> <div class="DistributorName">Taro Pharmaceuticals U.S.A., Inc.</div></p>
</body></html>
